|
1）McDonnell DP, Mangelsdorf DJ, Pike JW, et al. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science. 1987; 235: 1214-47
|
|
|
|
2）Nakano C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol. 2012; 7: 810-9
|
|
|
|
|
|
3）Obi Y, Hamano T, Ichimaru N, et al. Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study. Clin Endocrinol Metab. 2014; 99: 527-35
|
|
|
|
|
|
4）Shroff R, Aitkenhead H, Costa N, et al. Normal 25-hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD. J Am Soc Nephrol. 2015 (in press)
|
|
|
|
|
|
5）Bhan I, Powe CE, Berg AH, et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int. 2012; 82: 84-9
|
|
|
|
|
|
6）Johnsen MS, Grimnes G, Figenschau Y, et al. Serum free and bio-available 25-hydroxyvitamin D correlate better with bone density than serum total 25-hydroxyvitamin D. Scand J Clin Lab Invest. 2014; 74: 177-83
|
|
|
|
|
|
7）Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012; 367: 40-49
|
|
|
|
|
|
8）Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003; 326: 469
|
|
|
|
|
|
9）Glendenning P, Zhu K, Inderjeeth C, et al. Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: A randomized controlled trial. J Bone Miner Res. 2012; 27: 170-6
|
|
|
|
|
|
10）Smith H, Anderson F, Raphael H, et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2007; 46: 1852-7
|
|
|
|
|
|
11）Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010; 303: 1815-22
|
|
|
|
|
|
12）Kusunoki Y, Matsui I, Hamano T, et al. Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype. Kidney Int. 2015; (in press)
|
|
|
|
|
|
13）de Seigneux S, Courbebaisse M, Rutkowski JM, et al. Proteinuria increases plasma phosphate by altering its tubular handling. J Am Soc Nephrol. 2015; 26: 1608-18
|
|
|
|
|
|
14）Abbasian N, Burton JO, Herbert KE, et al. Hyperphosphatemia, phosphoprotein phosphatases, and microparticle release in vascular endothelial cells. J Am Soc Nephrol. 2015; 26: 2152-62
|
|
|
|
|
|
15）Dursun I, Poyrazoglu HM, Gunduz Z, et al. The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease. Nephrol Dial Transplant. 2009; 24: 2511-8
|
|
|
|
|
|
16）Sakaguchi Y, Fujii N, Shoji T, et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One. 2014; 9: e116273
|
|
|
|
|
|
17）Sakaguchi Y, Iwatani H, Hamano T, et al. Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease. Kidney Int. 2015; 88: 833-42
|
|
|
|
|